2 Information about Risankizumab
|
Marketing authorisation indication |
Risankizumab (Skyrizi, AbbVie) has a marketing authorisation 'for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy'. |
|---|---|
|
Dosage in the marketing authorisation |
Risankizumab is administered by subcutaneous injection at a dose of 150 mg at weeks 0 and 4, and then every 12 weeks. Consideration should be given to stopping treatment in people whose condition has shown no response after 16 weeks of treatment. |
|
Price |
The list price of risankizumab is £3,326.09 per 150 mg dose (excluding VAT; price as quoted in company's submission). The company has a commercial arrangement. This makes risankizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount. |